Compare Kinross Gold Corporation (KGC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinross Gold Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? Kinross Gold Corporation trades at $24.29 (market cap $28.07B), while State Street SPDR S&P Biotech ETF trades at $151.92. The key difference: Kinross Gold Corporation pays a 0.62% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Kinross Gold Corporation nearer its low. Which is the better fit depends on your goals.
| KGC | XBI | |
|---|---|---|
Market Cap | $28.07B | — |
Sector | Basic Materials | Broad Market / Factor |
52-Week High | $38.06 | $164.28 |
52-Week Low | $15.42 | $85.16 |
Enterprise Value | $26.62B | — |
Dividend Yield | 0.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kinross Gold (KGC) trades at $23.43, up 3.79% on the day, with strong fundamentals including a P/E of 9.59 and robust profitability metrics. The company has consistently beaten earnings expectations in recent quarters, with Q2 2026 results due July 29, 2026. Technical indicators show bearish momentum despite oversold RSI conditions, while analyst consensus remains strongly bullish with a $37.20 price target representing 59% upside potential.
KGC presents a compelling value opportunity with attractive valuation multiples and strong cash flow generation. Key risks include gold price volatility and rising operational costs. The stock's current discount to analyst targets and improving financial trajectory suggest potential for significant appreciation, though investors should monitor Q2 earnings and gold market dynamics closely.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
